Based on the AEON Biopharma, Inc. stock forecast from 1 analysts, the average analyst target price for AEON Biopharma, Inc. is USD 5.60 over the next 12 months. AEON Biopharma, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AEON Biopharma, Inc. is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, AEON Biopharma, Inc.’s stock price was USD 1.00. AEON Biopharma, Inc.’s stock price has changed by -9.09% over the past week, +45.12% over the past month and -81.72% over the last year.
No recent analyst target price found for AEON Biopharma, Inc.
No recent average analyst rating found for AEON Biopharma, Inc.
Company Overview AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California. Address: 5 Park Plaza, Irvine, CA, United States, 92614 Read Less
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoin...Read More
Frequently Asked Questions About AEON Biopharma, Inc. (AEON) Stock
Based on ratings from 1 analysts AEON Biopharma, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on AEON's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AEON is USD 5.60 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on AEON's stock to indicate if its overvalued.
The last closing price of AEON's stock was USD 1.00.
The most recent market capitalization for AEON is USD 0.04B.
Based on targets from 1 analysts, the average taret price for AEON is projected at USD 5.60 over the next 12 months.
This means that AEON's stock price may go up by +460.00% over the next 12 months.
We can't find any ETFs which contains AEON Biopharma, Inc.'s stock.
As per our most recent records AEON Biopharma, Inc. has 5 Employees.
AEON Biopharma, Inc.'s registered address is 5 Park Plaza, Irvine, CA, United States, 92614.
You can get more information about it from AEON Biopharma, Inc.'s website at https://www.aeonbiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About AEON Biopharma, Inc. (AEON) Stock
Based on ratings from 1 analysts AEON Biopharma, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on AEON's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AEON is USD 5.60 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on AEON's stock to indicate if its overvalued.
The last closing price of AEON's stock was USD 1.00.
The most recent market capitalization for AEON is USD 0.04B.
Based on targets from 1 analysts, the average taret price for AEON is projected at USD 5.60 over the next 12 months.
This means that AEON's stock price may go up by +460.00% over the next 12 months.
We can't find any ETFs which contains AEON Biopharma, Inc.'s stock.
As per our most recent records AEON Biopharma, Inc. has 5 Employees.
AEON Biopharma, Inc.'s registered address is 5 Park Plaza, Irvine, CA, United States, 92614.
You can get more information about it from AEON Biopharma, Inc.'s website at https://www.aeonbiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AEON !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
